Telix Pharmaceuticals Limited
Company Name | Telix Pharmaceuticals Limited |
Stock Symbol | TLX |
On July 22, 2025, Telix disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.”
On this news, Telix’s stock price fell $1.70, or 10.4%, to close at $14.58 per share on July 23, 2025, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Telix Pharmaceuticals Limited investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.